MD Anderson Cancer Center

Women are Reshaping the AI Talent Landscape New Research Shows Exponential Global Growth

Retrieved on: 
Wednesday, March 20, 2024
Research, Microsoft, Boston Consulting Group, Health, Organization, University, Apple, Woman, Amazon, Science, Intelligence, Roche, Meta, Female, ETS, Big, Data, MD Anderson Cancer Center, Engineering, Medical device

Zeki's AI dataset is the only of its kind in the world--- including more than 133,000 individuals and over 2 million unique data points. In this Women in AI 2024 report, Zeki has ranked and scored 33,000+ women from 109 countries educated or working at over 4,300 universities or employed by over 42,000 companies or organisations globally.

Key Points: 
  • In this Women in AI 2024 report , Zeki has ranked and scored 33,000+ women from 109 countries educated or working at over 4,300 universities or employed by over 42,000 companies or organisations globally.
  • These precise, data-led insights focus on where and how to find, attract, and retain top women in AI.
  • University Attraction- US universities are training increasing numbers of top women in AI, yet women only represent roughly 22% of scientists and engineers in major US university AI labs.
  • For expanded insights, see Zeki's flagship report, the State of AI Talent 2024 , for actionable intelligence on the countries, companies, universities, and sectors winning and losing in the race for top AI talent.

Rice Biotech Launch Pad adds William McKeon to external advisory board

Retrieved on: 
Thursday, March 14, 2024
Harris Health System, Research, Launch pad, Growth, Bill, Goldman Sachs, Rice University, Trustee, Integration, Patient, Stanford University Medical Center, Neuroscience, University, Faculty, Medtronic, MicroPort, CTMC, Roger Williams University, Texas Medical Center, Argonne National Laboratory, Rice, Jefferies, Greater Houston Partnership, College of Engineering (KNUST), MD Anderson Cancer Center, McKeon, Pharmaceutical industry

HOUSTON, March 14, 2024 /PRNewswire/ -- Rice University today announced the addition of William McKeon to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.

Key Points: 
  • HOUSTON, March 14, 2024 /PRNewswire/ -- Rice University today announced the addition of William McKeon to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "The appointment of a figure like Bill McKeon, who heads the largest medical city in the world at TMC, to the Launch Pad's external advisory board marks another highpoint of our commitment to the city of Houston," said Paul Wotton , executive director and chairman of the Rice Biotech Launch Pad.
  • "We are delighted to welcome Bill McKeon to the Launch Pad's remarkable external advisory board as he is a truly skilled leader whose local influence and strategic guidance will help elevate the Rice Biotech Launch Pad as a source for clinical advancements," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the accelerator.
  • "I am honored to join the exceptional advisory board of the Rice Biotech Launch Pad," said McKeon.

Leading-Edge Technologies, Data and Insights: Bio-IT World Conference & Expo Highlights the Drivers of Precision Medicine Innovation

Retrieved on: 
Thursday, March 14, 2024
Molecule, Learning Technology Partners, Personalized medicine, Organization, Conference, Innovation, Biotechnology, AstraZeneca, Partnering, Convention, Virtual humans, Data science, Drug discovery, RWE, Bias, Shape, Social media, Stargate Atlantis, RWD, Transformation, Bristol Myers Squibb, Digital twin, Student, LDN, Investment, Vacuum, RDN, Water, Machine learning, MD Anderson Cancer Center, Pharmaceutical industry

BOSTON, March 14, 2024 /PRNewswire/ -- Life science innovation doesn't happen in a vacuum. It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.

Key Points: 
  • It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.
  • From April 15-17, more than 3,000 pharmaceutical, biotechnology and IT leaders will gather for the 23rd annual Bio-IT World Conference & Expo in Boston to put this model into action.
  • "Precision medicine is at a tipping point as both scientific and computing capabilities explode," said Cindy Crowninshield, RDN, LDN, Executive Event Director.
  • This year, the Bio-IT World conference will focus on how to keep the creative pipeline flowing by bringing rising scientists into the fold.

Bio-Path Holdings Reports Full Year 2023 Financial Results

Retrieved on: 
Friday, March 8, 2024
Division, Research, AML, University, Clinical trial, Chronic lymphocytic leukemia, CLL, Holding, MD Anderson Cancer Center, Patient, D.O, Lymphoma, KOL, Pharmaceutical industry

“2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Key Points: 
  • “2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.
  • As of December 31, 2023, the Company had cash of $1.1 million, compared to $10.4 million as of December 31, 2022.
  • Net cash provided by financing activities for the year ended December 31, 2023 was $2.2 million.
  • ET to review these full-year 2023 financial results and to provide a general update on the Company.

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Retrieved on: 
Thursday, March 7, 2024
Master of Science, Breast cancer, BCT, Division, CMO, Doctor of Philosophy, MD, University, Quality of life, TSX, Letter, Vaccine, Breast, MD Anderson Cancer Center, Cancer, Therapy, Associate professor, Patient, Survival, Disease, Prostate cancer, Pharmaceutical industry

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell

Key Points: 
  • Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell
    PHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) --  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, Associate Professor, Department of Investigational Cancer Therapeutics and Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.
  • “We are ecstatic about working with the team led by Dr. Pohlmann,” stated Dr. Williams, BriaCell’s President & CEO.
  • “We strongly believe in the therapeutic potential of our novel personalized next-generation vaccine platform and this agreement will be invaluable to us as we advance the clinical development of our off-the-shelf therapies to those cancer patients with persistent unmet medical needs.”
    “Through this agreement, we expect to further our understanding of our novel immunotherapy’s mechanism of action and its use in breast and prostate cancer patients,” stated Dr. Giuseppe Del Priore, BriaCell’s CMO.
  • “Our shared goal is to improve the survival and quality of life in cancer patients who are fighting a disease with a poor prognosis and a short life expectancy.”

TOMI Expands SteraMist iHP Corporate Service Contracts and Clients

Retrieved on: 
Thursday, March 7, 2024
Hydrogen, DARPA, Acquisition, Pfizer, Hospital, Rocky, Restaurant, Hydrogen peroxide, Food safety, Disinfectant, Annual report, Health, Growth, Cell, Monroe Dunaway Anderson, Horsepower, Meat, University, School, Supervisor, Decontamination, MD Anderson Cancer Center, Police, Medication, Trust, Paint, Corporation, Partnership

FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.

Key Points: 
  • FREDERICK, Md., March 07, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced an expansion in its SteraMist iHP Corporate Service contracts, reaffirming its position as a leading provider of decontamination services to corporate clients in the life sciences industry.
  • SteraMist iHP technology is becoming the standard decontamination technology in the life sciences sector and academic institutions with a broad spectrum of clients equipped with mobile systems, custom integrations, and service contracts.
  • In a notable development, Rising Pharmaceuticals has entered into an ongoing annual contract with TOMI’s SteraMist iHP Corporate Service following the acquisition of a building previously serviced by the team.
  • SteraMist iHP Corporate Service managed to decontaminate our entire facility quickly without causing harm to the infrastructure or our sensitive equipment.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets

Retrieved on: 
Tuesday, March 5, 2024
Trichloroethylene, Therapy, CG1, Doctor of Philosophy, TCE, MD, Immunotherapy, Monroe Dunaway Anderson, AACR, Cathepsin G, Annual general meeting, Safety, MD Anderson Cancer Center, University, Mass spectrometry, Myeloid leukemia, TCR, Malignancy, CTSG, Cancer, Pharmaceutical industry

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.

Key Points: 
  • The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex.
  • The complex is abundantly expressed on leukemic cells, but not on normal cells, allowing CBX-250 to target cancer cells efficiently while sparing normal myeloid cells.
  • “Nominating CBX-250 as a development candidate validates our initial scientific hypothesis, and it brings us a step closer to entering the clinic and ultimately helping to cure cancer,” said Briggs Morrison, Chief Executive Officer of Crossbow.
  • Working with MD Anderson’s ORBIT platform, a core component of the institution’s Therapeutics Discovery division , Dr. Molldrem led the development of a TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for the development of off-the-shelf cancer immunotherapies.

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Neoplasm, Cetuximab, Jefferies Group, Research, Chemistry, Nivolumab, Table, NETS, IRS, NK, Pancreatic cancer, Head, 5T4, DCR, Investigational New Drug, Escape Room, SCCHN, Interim, MD Anderson Cancer Center, Congress, Net, Three Months, International Financial Reporting Standards, CMC, Immune system, International, ESMO, Neutrophil extracellular traps, University, STAT3, AACR, CM24, Conference, Tumor microenvironment, MOA, IND, Insurance, Acquisition, ADS, Drug resistance, Food, Average cost, CEACAM1, PDAC, Administration, Patient, Pharmaceutical industry

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
Monday, March 4, 2024
Therapy, Head, Neoplasm, Neck, CLS, AML, Part, TME, Sale, Pembrolizumab, Multiple myeloma, Bristol Myers Squibb, Symantec Endpoint Protection, TPS, Hyponatremia, Cytokine, Hypertension, Tumor microenvironment, Patient, Immunoglobulin A, MD Anderson Cancer Center, Hyperlipidemia, Disease, Biology, HNSCC, Hypercholesterolemia, CPS, PD-L1, Cancer, Pharmaceutical industry

Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.

Key Points: 
  • Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.
  • MTEM intends to initiate a study of MT-0169 in CD38+ acute leukemias in collaboration with MD Anderson Cancer Center.
  • Additional details on each of these participant’s clinical profile and response to the investigational treatment are provided below.
  • MTEM plans on initiating an investigator sponsored trial with MD Anderson Cancer Center to evaluate MT-0169 in relapsed or refractory CD38+ AML patients.